不同化疗方案在Ⅱ～Ⅲ期结肠癌患者中的应用研究

Application of Different Chemotherapy Regimens in Patients With Stage Ⅱ～Ⅲ Colon Cancer

目的研究辅助化疗XELOX方案与mFOLFOX6方案在Ⅱ~Ⅲ期结肠癌患者中的应用效果。方法回顾性分析2015年10月-2018年10月医院治疗的58例结肠癌患者临床资料,依据根治性手术切除后化疗方案的不同将其分为两组,将接受XELOX方案化疗的30例患者临床资料组成XELOX组,将接受mFOLFOX6方案化疗的28例患者临床资料组成m FOLFOX6组。观察两组生存情况及不良反应。结果 XELOX组神经毒性(43.33%)、口腔黏膜炎(20.00%)、腹泻(30.00%)、粒细胞减少(33.33%)、白细胞减少(30.00%)、血小板减少发生率(30.00%)低于mFOLFOX6组(71.43%、50.00%、67.86%、71.43%、60.71%、64.29%),差异有统计学意义(P <0.05);XELOX组、mFOLFOX6组无病生存率(80.00%、78.57%)、总生存率(86.67%、85.71%)相比,差异无统计学意义(P> 0.05)。结论辅助化疗XELOX方案用于Ⅱ~Ⅲ期结肠癌患者治疗中不良反应少,且可取得与mFOLFOX6方案相当的术后无病生存率、总生存率。

Objective To study the effect of adjuvant chemotherapy XELOX and mFOLFOX6 in patients with stage Ⅱ~Ⅱ colon cancer. Methods The clinical data of 58 patients with colon cancer treated in our hospital from October 2015 to October 2018 were retrospectively analyzed. They were divided into two groups according to the different chemotherapy regimens after radical surgical resection, and 30 patients received XELOX chemotherapy. The clinical data of patients were composed of XELOX group, and the clinical data of 28 patients receiving mFOLFOX6 chemotherapy were composed of mFOLFOX6 group. Observe survival and adverse reactions in both groups. Results The neurotoxicity(43.33%), oral mucositis(20.00%), diarrhea(30.00%), granulocytopenia(33.33%), leukopenia(30.00%), and thrombocytopenia(30.00%) in the XELOX group were lower than mFOLFOX6 Group(71.43%, 50.00%, 67.86%, 71.43%, 60.71%, 64.29%), the difference was statistically significant(P < 0.05);XELOX group, mFOLFOX6 group disease-free survival rate(80.00%, 78.57%). There were no significant differences in survival rates(86.67%, 85.71%)(P > 0.05). Conclusion Adjuvant chemotherapy XELOX regimen has fewer adverse reactions in the treatment of patients with stage Ⅱ~Ⅱ colon cancer, and can obtain disease-free survival rate and overall survival rate comparable to mFOLFOX6 regimen.